Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-03 19:04:33时区推断·⟳ 抓取 08-03 19:05:49·⚡ 决策 08-04 09:15:03 +14h09m·84.9 天前
Opus Genetics完成OPGx-LCA5三期试验入组
Opus Genetics完成OPGx-LCA5注册性三期入组，理论上推进首个LCA5相关遗传性视网膜疾病疗法的BLA路径。
📄 原文Investing.com↗ 原文
Opus Genetics completes enrollment in LCA5 gene therapy trial
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks RESEARCH TRIANGLE PARK, N.C. - Opus Genetics In…
不做 Opus Genetics（IRD.US）
三期入组完成是正面进度，但给药和topline仍远，缺少可量化短线收入或疗效催化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 报道OPGx-LCA5三期试验完成入组，预计2026年四季度启动给药、2027年底topline。市场反应:IRD最新价3.64美元，当日-1.89%。
关键理由
- Opus Genetics完成OPGx-LCA5注册性三期入组，理论上推进首个LCA5相关遗传性视网膜疾病疗法的BLA路径。
主要风险
- 受试者仍在6个月run-in期，预计2026年四季度才给药、2027年底才有topline数据，短线缺少读出。
- 该适应症为罕见病，当前披露没有患者数、定价、渗透率或Priority Review Voucher价值量化，难以估算收入/市值弹性。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中OPGx-LCA5患者数、定价、收入分成或PRV可交易价值的可靠量化证据。
检索:Opus Genetics OPGx-LCA5 Phase 3 enrollment LCA5 market size priority review voucher cash runway
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,245 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
RESEARCH TRIANGLE PARK, N.C. - Opus Genetics Inc. (NASDAQ:IRD) announced Monday that it has completed enrollment in its Phase 3 clinical trial evaluating OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease.
The trial was designed in collaboration with the U.S. Food and Drug Administration to support a potential Biologics License Application for what the company describes as a potential first approved therapy for patients with LCA5-associated inherited retinal disease, according to a press release statement.
The program was accepted into the FDA’s Rare Disease Evidence Principles program in May 2026. The company stated it may submit a BLA based on six-month efficacy data, with 12-month durability data provided during review.
"Achieving full enrollment in our registrational Phase 3 trial is a significant milestone for the OPGx-LCA5 program," said George Magrath, Chief Executive Officer of Opus Genetics.
The trial evaluates the safety and efficacy of a one-time subretinal administration of OPGx-LCA5 in patients with genetically confirmed LCA5-associated inherited retinal disease. The study includes a six-month run-in period in which patients serve as their own control.
Opus Genetics expects to initiate dosing in the fourth quarter of 2026, with topline data expected by the end of 2027. Participants are currently completing the run-in period.
OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy designations from the FDA. The company stated it expects OPGx-LCA5 may qualify for a Rare Pediatric Disease Priority Review Voucher upon approval.
LCA5-associated inherited retinal disease is an early-onset severe inherited retinal dystrophy caused by biallelic mutations in the LCA5 gene. OPGx-LCA5 uses an adeno-associated virus 8 vector to deliver a functional LCA5 gene to the outer retina.
Opus Genetics is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, developing gene therapies for inherited retinal diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
RESEARCH TRIANGLE PARK, N.C. - Opus Genetics Inc. (NASDAQ:IRD) announced Monday that it has completed enrollment in its Phase 3 clinical trial evaluating OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease.
The trial was designed in collaboration with the U.S. Food and Drug Administration to support a potential Biologics License Application for what the company describes as a potential first approved therapy for patients with LCA5-associated inherited retinal disease, according to a press release statement.
The program was accepted into the FDA’s Rare Disease Evidence Principles program in May 2026. The company stated it may submit a BLA based on six-month efficacy data, with 12-month durability data provided during review.
"Achieving full enrollment in our registrational Phase 3 trial is a significant milestone for the OPGx-LCA5 program," said George Magrath, Chief Executive Officer of Opus Genetics.
The trial evaluates the safety and efficacy of a one-time subretinal administration of OPGx-LCA5 in patients with genetically confirmed LCA5-associated inherited retinal disease. The study includes a six-month run-in period in which patients serve as their own control.
Opus Genetics expects to initiate dosing in the fourth quarter of 2026, with topline data expected by the end of 2027. Participants are currently completing the run-in period.
OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy designations from the FDA. The company stated it expects OPGx-LCA5 may qualify for a Rare Pediatric Disease Priority Review Voucher upon approval.
LCA5-associated inherited retinal disease is an early-onset severe inherited retinal dystrophy caused by biallelic mutations in the LCA5 gene. OPGx-LCA5 uses an adeno-associated virus 8 vector to deliver a functional LCA5 gene to the outer retina.
Opus Genetics is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, developing gene therapies for inherited retinal diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。